Chairwoman of the Board
Behshad Sheldon is the founder and Chairwoman of the Board of Directors for FORCE. She is the former President and CEO of Braeburn and through this role came to be a passionate defender of the rights of people with Opioid Use Disorder.
Ms Sheldon joined Braeburn as one of its founding members in Dec 2012 with the objective of building a company dedicated to patients with underserved serious central nervous system diseases. With expertise in research as well as commercialization, she brought Probuphine, a 6-month implant for opioid addiction, to market while driving additional investment in long-acting weekly and monthly buprenorphine injectable medicines through in-licensing of the CAM-2038 products.
Prior to Braeburn, she spent 10 years at Otsuka Pharmaceuticals, co-founded the Otsuka Princeton office in 2002. She served as Senior Vice President of Patient and Branding Strategy at Otsuka America Pharmaceutical, Inc. Ms. Sheldon was responsible for the overall strategic marketing vision of Otsuka global and US products (both in-house and in-licensed) in OAPI and OPDC, respectively. Ms. Sheldon served as Vice President of Global Marketing at Otsuka Pharmaceutical Development & Commercialization, Inc.
Highly regarded in the industry for her strategic marketing expertise, Ms. Sheldon joined Otsuka in July 2002, as Vice President, Neuroscience Global Commercialization to manage Otsuka's alliance with Bristol-Myers Squibb. Her outstanding performance led to increased responsibilities as Vice President, Global Marketing and included all products representing global business opportunities for Otsuka. She influenced teams working on all aspects of drug development, from drug discovery through life cycle management of launched products, working with Tokushima discovery in identifying unmet medical needs and future directions in development of Otsuka's new products.
Prior to joining Otsuka, she served as a Senior Director in Global Marketing at Bristol-Myers Squibb, where she was responsible for the marketing success of blockbuster drugs Plavix and Glucophage. Ms. Sheldon's other commercial experiences have included managing successful marketing initiatives at SmithKline Beecham, including Bactroban. She has been a Director of Cerecor Inc. since July 11, 2014. Ms. Sheldon served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in CNS, cardio-renal, pain, dermatology, and oncology. Ms. Sheldon holds a BS in Neuroscience from the University of Rochester.